NFKB1 and colorectal cancer: Inhibition of GSK‐3β can also reduce the proliferation of colorectal cancer cells by down‐regulating NF‐κB and NF‐κB‐mediated gene expression,39 which may benefit the clinical outcomes of patients suffering from colorectal cancer.40